Unique ID issued by UMIN | UMIN000036321 |
---|---|
Receipt number | R000040733 |
Scientific Title | Randomized, double-blind, placebo-controlled parallel-group comparative study to evaluate the effect of nicotinamide mononucleotide (NMN) on the body composition in elderly persons |
Date of disclosure of the study information | 2019/06/01 |
Last modified on | 2021/03/02 18:05:15 |
Randomized, double-blind, placebo-controlled parallel-group comparative study to evaluate the effect of nicotinamide mononucleotide (NMN) on the body composition in elderly persons
The study to evaluate the effect of nicotinamide mononucleotide (NMN) on the body composition in elderly persons
Randomized, double-blind, placebo-controlled parallel-group comparative study to evaluate the effect of nicotinamide mononucleotide (NMN) on the body composition in elderly persons
The study to evaluate the effect of nicotinamide mononucleotide (NMN) on the body composition in elderly persons
Japan |
healthy subjects
Adult |
Others
NO
To evaluate the effect of NMN oral administration on the body composition in elderly persons
Efficacy
Exploratory
Not applicable
To evaluate the skeletal muscle index by the bioelectrical impedance analysis
1) To evaluate the parameters related to glucose metabolism
2)To evaluate the vascular endothelial function by FMD
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
2
Prevention
Food |
Subjects receive 250 mg/day of NMN for 12 weeks.
Subjects receive placebo for 12 weeks.
65 | years-old | <= |
Not applicable |
Male
1)the healthy subjects who agree to the study.
2)Body Mass Index 22-28
3)no smoking history
1)The subjects who take functional food that may affect the trial
2)The subjects who take more than one hour daily exercise for more than 6 months
3)The subjects with the history of serious disease (malignant neoplasms, cardiac failure and myocardial infarction )
4)The subjects with chronic disease
5)The subjects who take medicines
6)The subjects with allergic disorders.
7)The subjects who participate in any clinical trial within 90 days of the commencement of the trial
8)The subjects judged as ineligible by clinical investigators
42
1st name | Masaki |
Middle name | |
Last name | Igarashi |
The Unversity of Tokyo Hospital
Department of Diabetes and Metabolic Diseases
113-8655
7-3-1 Hongo Bunkyo-ku
03-3815-5411
igarashi-tky@umin.ac.jp
1st name | Masaki |
Middle name | |
Last name | Igarashi |
The University of Tokyo Hospital
Department of Diabetes and Metabolic Diseases
113-8655
7-3-1 Hongo Bunkyo-ku
03-3815-5411
igarashi-tky@umin.ac.jp
Department of Diabetes and Metabolic Diseases, The University of Tokyo Hospital
Mitsubishi Corporation Life Sciences Limited
Profit organization
The University of Tokyo, Clinical Research Review Board
7-3-1 Hongo Bunkyo-ku
03-5841-0818
ethics@m.u-tokyo.ac.jp
NO
2019 | Year | 06 | Month | 01 | Day |
Unpublished
Completed
2019 | Year | 02 | Month | 07 | Day |
2019 | Year | 03 | Month | 29 | Day |
2019 | Year | 06 | Month | 01 | Day |
2019 | Year | 09 | Month | 30 | Day |
2019 | Year | 03 | Month | 27 | Day |
2021 | Year | 03 | Month | 02 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040733
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |